SIDEBAR: How the MEDCAC Panelists Voted
Grading their responses on a 5-point scale, where 5 represented the highest level of confidence, Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) members were asked the following questions:
- How confident are you that there is adequate evidence to determine if the benefits outweigh the harms of lung cancer screening with low-dose CT? Mean score = 2.2222.
- How confident are you that the harms of lung cancer screening with low-dose CT if implemented in the Medicare population will be minimized? Mean score = 2.3333.
- How confident are you that clinically significant evidence gaps remain regarding the use of low-dose CT for lung cancer screening in the Medicare population outside a clinical trial? Mean score = 4.4444. ■
Related Articles
Medicare Advisory Panel Cast Doubts on Lung Cancer Screening, Leaving Advocates Dismayed but Undaunted
On April 30, 2014, the Centers for Medicare & Medicaid Services (CMS) convened the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) to assess the value of low-dose computed tomography (CT) lung cancer screening in the Medicare population. After a decades-long battle,...
SIDEBAR: MEDCAC Roster
Rita Redberg, MD, MS, Chair
Professor of Medicine
UCSF School of Medicine
Division of Cardiology
University of California,
San Francisco, Medical Center
Art Sedrakyan, MD, PhD, Vice Chair
Associate Professor and Director
Patient Centered Comparative Outcomes Research Program
Weill Cornell Medical...
